key: cord-0253762-2o5wk2sb
authors: Otter, A. D.; Bown, A.; D'Arcangelo, S.; Bailey, D.; Semper, A.; Hewson, J.; Catton, M.; Perumal, P.; Sweed, A.; Jones, J.; Harvala, H.; Lamikanra, A.; Zambon, M.; Andrews, N.; Whitaker, H.; Linley, E.; Mentzer, A. J.; Skelly, D.; Knight, J.; Klenerman, P.; PHE Porton Euroimmun testing group,; Amirthalingam, G.; Taylor, S.; Rowe, C.; Vipond, R.; Brooks, T.
title: Implementation and extended evaluation of the Euroimmun Anti-SARS-CoV-2 IgG assay and its contribution to the United Kingdom's COVID-19 public health response
date: 2021-10-28
journal: nan
DOI: 10.1101/2021.10.26.21265497
sha: f47cf5608aeca9da6e067eb6a9314b5ce33a925b
doc_id: 253762
cord_uid: 2o5wk2sb

In March 2020, the Rare and Imported Pathogens Laboratory at Public Health England, Porton Down, was tasked by the Department of Health and Social Care with setting up a national surveillance laboratory facility to study SARS-CoV-2 antibody responses and population-level sero-surveillance in response to the growing SARS-CoV-2 outbreak. In the following 12 months, the laboratory tested more than 160,000 samples, facilitating a wide range of research and informing PHE, DHSC and UK government policy. Here we describe the implementation and use of the Euroimmun anti-SARS-CoV-2 IgG assay and provide an extended evaluation of its performance. We present a markedly improved sensitivity of 91.39% ([≥]14 days 92.74%, [≥]21 days 93.59%) compared to our small-scale early study, and a specificity of 98.56%. In addition, we detail extended characteristics of the Euroimmun assay: intra- and inter-assay precision, correlation to neutralisation and assay linearity.

In March 2020, the Rare and Imported Pathogens Laboratory at Public Health 28

England, Porton Down, was tasked by the Department of Health and Social Care with 29 setting up a national surveillance laboratory facility to study SARS-CoV-2 antibody 30 responses and population-level sero-surveillance in response to the growing SARS-31

CoV-2 outbreak. In the following 12 months, the laboratory tested more than 160,000 32 samples, facilitating a wide range of research and informing PHE, DHSC and UK 33 government policy. Here we describe the implementation and use of the Euroimmun 34 anti-SARS-CoV-2 IgG assay and provide an extended evaluation of its performance. 35

We present a markedly improved sensitivity of 91.39% (≥14 days 92.74%, ≥21 days 36 93.59%) compared to our small-scale early study, and a specificity of 98.56%. In 37 addition, we detail extended characteristics of the Euroimmun assay: intra-and inter-38 assay precision, correlation to neutralisation and assay linearity. only samples taken ≥14 days post-symptom onset, the sensitivity was 73.42% (95%CI 164 62.28-82.73) and at ≥21 days, the sensitivity was 74.67% (95%CI 63.30-84.01) 16 . 165 Subsequent to our initial establishment of the serosurveillance service using the 166 Euroimmun assay, further commercial immunoassay platforms and kits were 167 evaluated at the request of the DHSC to inform decisions on the use of high-throughput 168 assays by NHS laboratories for the detection of anti-SARS-CoV-2 antibodies in patient 169 samples 13, 17 . As part of this work, we extended our evaluation of the Euroimmun 170 assay. Due to the limited samples and volumes available for the evaluation of high-171 throughput serology platforms, the panels differed slightly between our initial 172 Euroimmun evaluation and subsequent other commercial assay evaluations 173 performed by PHE Porton Down 15 . For the extended evaluation, an additional 592 174 PCR-positive samples that were used for the different verifications of the higher-175 throughput platforms (including a head-to-head study 13 ) were tested using the 176 Euroimmun anti-SARS-CoV-2 IgG assay. 177 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (Figure 1, Table 1, Figure 3) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. ; https://doi.org/10.1101/2021.10.26.21265497 doi: medRxiv preprint for differences in sensitivities with some samples potentially taken too soon after onset 207 of symptoms to identify any detectable antibody response. Conversely, many of the 208 extended evaluation samples, by their nature, were taken from convalescent patients 209 who had had sufficient interval post onset to generate a strong antibody response. 210

However, it should also be noted that no normalisation for sample demographics (for 211 example differences in geographic location, gender, ethnicity or patient age-ranges) 212 had been applied between datasets, so may have occurred and contributed to 213 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. ; https://doi.org/10.1101/2021.10.26.21265497 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. ; https://doi.org/10.1101/2021.10.26.21265497 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. ; https://doi.org/10.1101/2021.10.26.21265497 doi: medRxiv preprint 6. Further assay characteristics 240 To determine the precision of the Euroimmun assay, five pooled patient samples were 241 used in the absence of an international standard or calibrant at the time to generate a 242 dilution series for linearity and to determine inter-and intra-assay variation, testing five 243 replicates each over five days. The intra-assay and inter-assay variations were found 244 to be <7% and <5% covariance (CV), respectively, indicating high precision when 245 comparing samples across multiple days and replicate samples (Table S1) . 246

Similarly, the dilution series was used to determine the linear range of the assay, with 247 an R 2 value of 0.985 (Figure 4) . As more standards became available, the NIBSC 248

Anti-SARS-CoV-2 Antibody Diagnostic Calibrant was serially diluted to generate 249 additional linearity data, providing a similar R 2 value of 0.955 (Figure 4) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. ; https://doi.org/10.1101/2021.10.26.21265497 doi: medRxiv preprint determining population-level exposure to SARS-CoV-2, additional studies were 323 conducted to determine the feasibility of using lateral flow device antibody tests. On 324 request from DHSC, a study was performed on emergency service workers to evaluate 325 the utility of home antibody testing kits; EDSAB-HOME (Evaluating Detection of 326 SARS-CoV-2 AntiBodies at HOME). Capillary blood samples from >2,500 volunteers 327 were tested on different lateral flow devices and a contemporaneous venous sample 328 was tested on the Euroimmun assay as the reference test 18 . 329 Euroimmun assay was used throughout to characterise the serostatus of all study 334 samples which by completion of the final follow-up samples at 1 year, will number 335 more than 13,000 samples. This data helped to define the proportion of this HCW 336 cohort who seroconverted, and was used to monitor the longitudinal antibody 337 response and rate of decline of anti-S1 IgG antibodies 6 and to investigate the 338 relationship between peak anti-S1 IgG titre and neutralising antibody titre 21 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. were available since January 2020, these require significant quality control to ensure 371 consistent diagnosis across batches of samples to ensure consistent sensitivity. 372

Similarly, in-house assays can also suffer from logistical and supply issues for 373 specially manufactured components (recombinant proteins etc). Commercial assays 374 became rapidly available with the spread of SARS-CoV-2 in early 2020, however 375 supply and logistical issues were also evident with the global spread of SARS-CoV-2, 376 so this should be a factor in deciding on assays for serosurveillance. 377 378 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 1, Figure 2) . This data is supported by other studies, which have 383 shown similar high sensitivities of 90% 23 , 96% 24 and 100% 25 . The initial evaluation 384 suggested a moderate sensitivity for the Euroimmun assay, but this is likely a reflection 385 of the early stages of the pandemic, when serum from patients with confirmed COVID-386 19 were extremely difficult to obtain, disease onset was poorly characterised and little 387 convalescent material was available. This limited the number of samples, as many of 388 the original evaluation samples were obtained from patients with mild disease within 389 the community, so in using these particular samples, this could have resulted in lower 390 sensitivity than anticipated, due to mild infections and resulting in lower antibody 391 responses than those with severe infections or those requiring hospitalisation 26 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 28, 2021. ; https://doi.org/10.1101/2021.10.26.21265497 doi: medRxiv preprint

World Health Organization. COVID-19 Weekly Epidemiological Update 22

Novel coronavirus disease (Covid-19): The first two patients in 471 the UK with person to person transmission

Retrospective screening of routine respiratory samples 474 revealed undetected community transmission and missed intervention 475 opportunities for SARS-CoV-2 in the United Kingdom

Page 29 of 36 Appendix 1